CN100453070C - Aseptic dry powder spray agent and production method in use for stopping the blood and diminishing inflammation in wound - Google Patents
Aseptic dry powder spray agent and production method in use for stopping the blood and diminishing inflammation in wound Download PDFInfo
- Publication number
- CN100453070C CN100453070C CNB2003101040277A CN200310104027A CN100453070C CN 100453070 C CN100453070 C CN 100453070C CN B2003101040277 A CNB2003101040277 A CN B2003101040277A CN 200310104027 A CN200310104027 A CN 200310104027A CN 100453070 C CN100453070 C CN 100453070C
- Authority
- CN
- China
- Prior art keywords
- wound
- aseptic
- spray
- sterile
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a sterile powder spraying agent used for wound hemostasis and inflammation resistance. The medicine of the present invention is a natural medicine with the functions of hemostasis and inflammation reduction or the effective parts or the monomer of the natural medicine. The present invention is characterized in that each spraying agent is composed of 0.01 to 0.2 g of medicines of wound hemostasis and inflammation reduction, and high-molecular natural assistant materials or synthesized assistant materials which have high biologic affinity and auxiliary function for wound healing, and can be absorbed with the wound healing. Thus, the acceptable medicament in the medicine is produced. The present invention has the integrated effects of bacterium prevention, hemostasis, acesodyne, itchy alleviation, inflammation reduction, blood circulating promotion, stasis elimination, etc., and can rapidly stop the blood of the wound and heal the wound without scars. The resent invention can absorb partial effused liquid of the wound, and can be dispersed and paved to form a protective film to be helpful for the wound healing. The product has convenient use and stable performance, and no stimulating function exists.
Description
Technical field
The present invention relates to a kind of wound that has antibiotic, hemostasis, antiinflammatory and wound is had a protective effect with sterile dry spray and production method.
Background technology
Because the development of medical skill and human living standard's raising, some human infectious diseases are in constantly decline and controlled.But, along with the increasing of mankind's activity amount, the quickening and the aggravation of moving speed, to be on the increase because of the injury that motion causes, extent of injury also continues to increase.The method for the treatment of wound so far still has many unsatisfactory places.Western medicine therapy mainly is to be operation stitching, the fixing treatment that is aided with antibacterials again with naturopathy.The traditional Chinese medical science is then based on blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain.Because all there are many antihygienic places in production, manufacturing, preservation, the use of Chinese medicine, make Chinese medicine on wound is used, be subjected to more limitation.In the tradition Chinese medicine many anti-inflammations, blood circulation promoting and blood stasis dispelling are arranged, wounds such as wound healing, granulation growth, Scar eliminating medicine remove are had the Chinese herbal medicine or the natural drug of Comprehensive Treatment effect.As the famous special product medical material-Radix Notoginseng in Yunnan, Rhizoma Paridis, solely nail, Caulis Et Folium Skimmiae etc., famous YUNNAN BAIYAO, YUNNAN HONGYAO, compound Herba Artemisiae Annuae liniment etc. are also arranged, doctor among the people also with the struggle of nature in invented many effective prescriptions.On minor cut or wound, using maximum at present is various adhesive bandages, but adhesive bandage is used on the big wound and then has inconvenience, and effect is also undesirable, as when changing dressings easily with the wound damage etc.Therefore, be necessary according to the analysis of existing medicine and the research of existing therapy,, develop a kind of sterile dry spray of the wound of wrapping up at the bigger wound of area, burn and inconvenience specially in conjunction with the utilization of the advantage and the modern biomedical of Chinese and western medicine.
Summary of the invention
The present invention has proposed a kind of wound hemostasis antiinflammatory sterile dry spray and production method thereof for addressing the above problem just.
Inventive principle is: have antibiotic at used medicine or its extract; hemostasis; pain relieving; antipruritic; antiinflammatory; comprehensive effect such as blood circulation promoting and blood stasis dispelling; wound is stopped blooding rapidly; healing; avoid staying on the basis of cicatrix; allocate into and have the bioaffinity height; wound healing there is assosting effect; can make natural adjuvant of self absorbed macromolecule or synthesis auxiliary material with wound healing; make acceptable preparation; enable to be sprayed on the wound with medicine; the absorption portion transudate; disperse; spread out and form layer protecting film; so that auxiliary wound healing is organized at last and assimilates in wound healing process.
The present invention realizes by following technical proposal: a kind of wound hemostasis antiinflammatory sterile dry spray, medicine in its content is crude drug or its effective site or the monomer with hemostasis and antiinflammation, it is characterized in that every spray is with containing wound hemostasis, anti-inflammation drugs 0.01～0.2g, surplus is for having the bioaffinity height, wound healing being had assosting effect, can make natural adjuvant of self absorbed macromolecule or synthesis auxiliary material with wound healing, make pharmaceutically acceptable medicament.
Described medicine is crude drug or its effective site or the monomer with hemostasis and antiinflammation, it specifically is Rhizoma Paridis, Radix Scutellariae, Radix Notoginseng, huangteng, Rhizoma Coptidis, Cortex Phellodendri, Radix Arnebiae (Radix Lithospermi), Herba Houttuyniae, Rabdosia rubescens, Radix Et Rhizoma Rhei, Radix Sanguisorbae, Herba Artemisiae Annuae, Radix Artemisia ordosicae, Herba Centellae, Radix Rubiae, Radix Cirsii Japonici, Herba Cirsii, Aloe, Caulis Et Folium Skimmiae, Herba Clinopodii, one or more natural drugs in the Flos Sophorae perhaps are YUNNAN BAIYAO, YUNNAN HONGYAO, the compound Herba Artemisiae Annuae liniment, purple snow cream (pellet), JINHUANG SAN, SANHUANG GAO, Shengji Yuhong Gao, Renshen Baidu San, one or more anti-inflammation hemostasia granulation promoting medicines or its extract in the four yellow cream.
Described adjuvant select for use have the bioaffinity height, to wound healing assosting effect is arranged, with the natural or synthesis auxiliary material of the absorbed macromolecule of wound healing self, specifically be in chitin (chitin), plant gum, gelatin, cellulose derivative, polyvinyl alcohol (PVA), the polylactic acid one or more.Add one or more spice in Radix Angelicae Sinensis oil, mugwort oil, Herba Artemisiae Annuae oil, Costusroot oil, nutgrass galingale oil, citron oil, cardamom oil, coumarin, the vanillin in the described adjuvant.
Wound hemostasis antiinflammatory provided by the invention with the production method of sterile dry spray is: with supplementary material through filtration, sterilization, aseptic ultramicronising handle, operation such as aseptic subpackaged makes, dry powder spray content---being prepared as of superfine sterile powder wherein:
One, lyophilization:
Under 10,000 grades condition, in an amount of water for injection, adding water for injection is diluted to volume required with medicine dissolution, and notes it is dissolved fully, adds water for injection to finally volume required.Filter, after the processing such as filter membrane coarse filtration of filtrate through filter paper and 0.4 μ m, under 100 grades condition, with the following membrane filtration of 0.2 μ m.Fine straining liquid is sent into frozen vacuum dryer, is chilled to-30 ℃～-40 ℃ fast, 2～3 hours, progressively slowly is warming up to 35 ℃～45 ℃ (needing 10 hours approximately).Take out goods, add aseptic adjuvant under aseptic condition, the porphyrize mixing carries out the aseptic ultramicronising of air-flowing type (or other) and pulverizes.
Can make required uniform superfine sterile semi-finished product.
Two, spray dry:
Under 10,000 grades condition, in an amount of water for injection, adding water for injection is diluted to volume required, adds water-soluble adjuvant again with medicine dissolution, and notes it is dissolved fully, adds water for injection to finally volume required.Filter, after the processing such as filter membrane coarse filtration of filtrate through filter paper and 0.4 μ m, under 100 grades condition, with the following membrane filtration of 0.2 μ m.Fine straining liquid is sent into sterile type and is sprayed dried machine and carry out the operation of aseptic spray drying, and the control liquor strength can make aseptic micropowder (particle diameter is at 0.01 μ m～10.0 μ m) below 5% and control flow velocity.If add adjuvant then again, take out goods, under aseptic condition, add aseptic adjuvant, the porphyrize mixing carries out the aseptic ultramicronising of air-flowing type (or other) and pulverizes.Can make required uniform superfine sterile semi-finished product.
Wound hemostasis antiinflammatory provided by the invention our experiments show that with the sterile dry spray:
1, stability: can place at normal temperatures 2 years, product is reliable and stable, and every index is all qualified, meets the requirements fully;
2, zest: do irritant experiment with Cavia porcellus, zest is 0 grade, does not promptly have significant change;
Drug effective region or monomeric general separation and Extraction:
Patent medicine or medical material, break into coarse powder, 8,6,6 times of calorimetric reflux, extract, of the ethanol with 50% ~ 80% 1 hour three times, merge extractive liquid,, be concentrated into 50% amount, with the activated carbon decolorizing of 0.1% solution amount, filtrate is too short, and (10 ~ 15cm) silicagel column remove impurity once is concentrated into 15% ~ 25% amount, 5 ~ 10 ℃ of placements are spent the night, ultra-filtration filters, vacuum concentration can get effective site (yield is generally 2 ~ 12%) to doing.
Separating monomer: effective site, with dry method or wet method upper prop, on silicagel column, separate, use following solvent: petroleum ether (60 ~ 80 ℃ of boiling points), petroleum ether-benzol mixture, benzene, benzene-ethyl acetate mixture, chloroform-methanol mixture eluting stream part, receipts connect stream part, and bioanalysis is followed the trail of active, and the active part vacuum concentration is to doing, dry thing corresponding solvent recrystallization gets monomer.
According to the physicochemical property of effective ingredient, can select supercritical (SC-CO for use
2) the extracting method extraction.Solvent can be selected CO for use
2, CO
2Carry ethanol, CO secretly
2Carry methanol etc. secretly, 45～65 ℃ of extraction temperature, extracting pressure 30 ~ 50Mpa resolves pressure 8 ~ 14Mpa, 42 ~ 67 ℃ of resolution temperatures.Advantage is that method belongs to clean and produces, and residual solvent is few in the extract.The amount of strict controlled condition and entrapment solvent can obtain different effective site until monomer.
Embodiment 1
The extraction of YUNNAN BAIYAO anti-inflammation effective site and the preparation of aseptic powder
The separation of step 1, YUNNAN BAIYAO effective ingredient:
Getting YUNNAN BAIYAO looses 1 kilogram, 8,6,6 times of calorimetric reflux, extract, of ethanol with 70% 1 hour three times, merge extractive liquid, is concentrated into 50% amount, with the activated carbon decolorizing of 0.1% solution amount, the silicagel column remove impurity of short (10cm) once, be concentrated into 20% amount, ultra-filtration filters is spent the night in 5～10 ℃ of placements, vacuum concentration can get the about 70g of effective site (yield is generally ~ 7%) of YUNNAN BAIYAO antibacterial anti hemorrhagic antiinflammatory to doing;
The preparation of step 2, the aseptic micropowder of YUNNAN BAIYAO extract:
Under 10,000 grades condition, the effective site 50g of the YUNNAN BAIYAO antibacterial anti hemorrhagic antiinflammatory of said extracted is dissolved in 500ml water for injection, and notes it is dissolved fully.Filter, after the processing such as filter membrane coarse filtration of filtrate through filter paper and 0.4 μ m, under 100 grades condition, with the following membrane filtration of 0.2 μ m.Fine straining liquid is sent into frozen vacuum dryer, is chilled to-30 ℃～-40 ℃ fast, 2～3 hours, progressively slowly is warming up to 35 ℃～45 ℃ (needing 10 hours approximately).Take out goods, add aseptic adjuvant chitin 200g under aseptic condition, the porphyrize mixing carries out the aseptic ultramicronising of air-flowing type (or other) and pulverizes.Can make required uniform superfine sterile semi-finished product;
The preparation of step 3, YUNNAN BAIYAO extract sterile dry spray:
Under aseptic condition, with the aseptic micropowder of above-mentioned YUNNAN BAIYAO extract, be encapsulated in by every 0.2g in the spray medicament reservoir of capsule (or bubble ocular form/or bar bar type), get final product 1350 of YUNNAN BAIYAO extract sterile dry sprays, each spray contains effective extract 0.052g, once uses up.
Embodiment 2
The preparation of Rhizoma Paridis extract sterile dry spray
The separation of step 1, Rhizoma Paridis effective ingredient:
Get 1 kilogram of Rhizoma Paridis, beat coarse powder, 8,6,6 times of calorimetric reflux, extract, of ethanol with 78% 1 hour three times, merge extractive liquid, is concentrated into 50% amount, activated carbon decolorizing with 0.1% solution amount, the silicagel column sucking filtration remove impurity of short (15cm) once is concentrated into 15% amount, and 5～10 ℃ of placements are spent the night, ultra-filtration filters, filtrate is stand-by;
The preparation of step 2, the aseptic micropowder of Rhizoma Paridis extract:
With above-mentioned stand-by liquid under 100 grades condition, with the following membrane filtration of 0.2 μ m.Fine straining liquid is sent into sterile type and is sprayed dried machine and carry out the operation of aseptic spray drying, can make the about 40g of aseptic powder (yield～4%).Take out whole aseptic powder, add aseptic adjuvant chitin 100g, hydroxypropyl cellulose 5g and Herba Artemisiae Annuae oil 1ml under aseptic condition, the porphyrize mixing carries out the aseptic ultramicronising of air-flowing type (or other) and pulverizes.Can make required uniform superfine sterile semi-finished product;
The preparation of step 3, Rhizoma Paridis extract sterile dry spray:
Under aseptic condition, with said extracted thing superfine sterile semi-finished product, in every is encapsulated in capsule (or bubble ocular form/or bar bar type) by 0.13g the dry powder spray medicament reservoir, get final product 1000 of Rhizoma Paridis extract sterile dry sprays, each spray contains effective extract 0.04g, once uses up.
Embodiment 3
The preparation of Radix Notoginseng extract sterile dry spray
The separation of step 1, compound components of panax notoginseng:
Get Radix Notoginseng reed 1 kilogram, beat coarse powder, the ethanol with 60% soaks into, with supercritical (SC-CO
2) the extracting method extraction.Solvent can be selected CO for use
2, CO
2Carry 10% methanol secretly, 45～65 ℃ of extraction temperature, extracting pressure 30～50Mpa resolves pressure 8～14Mpa, 42～67 ℃ of resolution temperatures.At CO
2Carry methanol extraction secretly and partly obtain the about 157g of Radix Notoginseng extract (yield～16%);
The preparation of step 2, the aseptic micropowder of Radix Notoginseng extract:
Above-mentioned extract is dissolved in 2000ml water for injection, under 100 grades condition, with the following membrane filtration of 0.2 μ m.Fine straining liquid is sent into sterile type and is sprayed dried machine and carry out the operation of aseptic spray drying, can make the about 132g of aseptic powder (yield～84%).Take out whole aseptic powder, add aseptic adjuvant chitin 100g, polylactic acid 45g and Radix Angelicae Sinensis oil 2ml under aseptic condition, the porphyrize mixing carries out the aseptic ultramicronising of air-flowing type (or other) and pulverizes.Can make required uniform superfine sterile semi-finished product 262g;
The preparation of step 3, Radix Notoginseng extract sterile dry spray:
Under aseptic condition, with said extracted thing superfine sterile semi-finished product, in every is encapsulated in capsule (or bubble ocular form/or bar bar type) by 0.25g the dry powder spray medicament reservoir, get final product 1048 of Radix Notoginseng extract sterile dry sprays, each spray contains effective extract 0.126g, once uses up.
Embodiment 4
The preparation of Sanguis Draxonis extract sterile dry spray
The separation of step 1, Sanguis Draxonis effective ingredient:
Get 1 kilogram of Sanguis Draxonis, 8,6,6 times of calorimetric reflux, extract, of ethanol with 80% 1 hour three times, merge extractive liquid,, be concentrated into 50% amount, with the activated carbon decolorizing of 0.1% solution amount, the silicagel column sucking filtration remove impurity of short (10cm) once, be concentrated into 25% amount, 10 ℃ of placements are spent the night, ultra-filtration filters, and filtrate is stand-by;
The preparation of step 2, the aseptic micropowder of Sanguis Draxonis extract:
With above-mentioned stand-by liquid under 100 grades condition, with the following membrane filtration of 0.2 μ m.Fine straining liquid is sent into sterile type and is sprayed dried machine and carry out the operation of aseptic spray drying, can make the about 300g of aseptic powder (yield～30%).Take out whole aseptic powder, add aseptic adjuvant chitin 1500g, gelatin 35g and vanillin 1g under aseptic condition, the porphyrize mixing carries out the aseptic ultramicronising of air-flowing type (or other) and pulverizes.Can make required uniform superfine sterile semi-finished product 1762g;
The preparation of step 3, Sanguis Draxonis extract sterile dry spray:
Under aseptic condition, with said extracted thing superfine sterile semi-finished product, in every is encapsulated in capsule (or bubble ocular form/or bar bar type) by 0.1g the dry powder spray medicament reservoir, get final product 17620 of Sanguis Draxonis extract sterile dry sprays, each spray contains effective extract 0.017g, once uses up.
Product study of pharmacy and effect:
1, the stability of spray
The lucifuge keeping at room temperature of 1,2,3,4 four samples of embodiment was placed 1,2,3,6 month, and through trial inspection, the jet amount of every spray is constant substantially, and effective ingredient does not change through check yet.Therefore, think that tentatively the various prescriptions of this inhalant all can reach the shelf-life about 1 year.
2, the hemostasis wound healing effect of spray
Get 4 of healthy rabbits, W:2.0～2.2kg, male and female half and half are divided into two groups, with the about 5 * 10cm of both sides, back unhairing
2, a depilation district does slight skin lesion test, is divided into administration district and check plot.Administration district administration 1 time (～0.1mg), check plot spray primary blank.Get 4 of healthy rabbits, W:2.0～2.2kg, male and female half and half are divided into two groups, with the about 5 * 10cm of both sides, back unhairing
2, a depilation district does the normal skin test, is divided into administration district and check plot.Administration district administration 1 time (～0.1mg), check plot spray primary blank.With marking the scratch of " # " shape on the syringe needle depilation district skin, diameter 2cm to stab epidermis, does not hinder corium, and hyporrhea degree of being is arranged before the administration.Administrated method is the same with normal skin, and opposite side compares.Another piece depilation district does the severe injury test, and with marking the scratch of " # " shape on the syringe needle depilation district skin, diameter 3cm to stab corium, has the more hemorrhage degree that is before the administration.Administrated method is the same with normal skin, and opposite side compares.Administration district administration 1 time (～0.1mg), check plot spray primary blank.After the administration, write down the situation of erythema that 1h, 24h, 48h medicine-feeding part occur, hemorrhage and wound healing respectively.
The result is as follows:
The result shows: trial target has hemostasis preferably, antiinflammatory and wound healing effect.
3, the antiinflammatory action of spray
Use the Whttle method, 30 of mices are divided into 3 groups at random, and 10 every group, the about 4cm of mouse back both sides unhairing
2Be administered twice at the unhairing position continuously, midfeather 30min, each spray (embodiment 1) intact (～0.052g), behind the administration 1h, the blue 0.2ml/ of mouse tail vein injection 0.5% ivens is the timely lumbar injection 0.7% acetic acid 0.2ml/10g in back only, puts to death mice behind the 15min, and intraperitoneal injection of saline 5ml gently rubs the back and extracts peritoneal fluid, centrifugal, supernatant is measured optical density value in the 620nm place, calculate and comparable group differences significance, the results are shown in following table:
Conclusion: this spray has antiinflammatory action preferably, with the blank group difference of highly significant is arranged relatively.
4, the irritation test of spray
Get 4 of healthy rabbits, W:2.0～2.2kg, male and female half and half are divided into two groups, with the about 5 * 10cm of both sides, back unhairing
2, a depilation district does the normal skin test, is divided into administration district and check plot.Administration district administration 1 time (～0.1mg), check plot spray primary blank.Another piece depilation district makes the injured skin irritation test, and with marking the scratch of " # " shape on the syringe needle depilation district skin, diameter 2cm to stab epidermis, does not hinder corium, and hyporrhea degree of being is arranged before the administration.Administrated method is the same with normal skin, and opposite side compares.Administration district administration 1 time (～0.1mg), check plot spray primary blank.Behind the administration 24h, write down 1h, 24h, 48h, the erythema of 72h medicine-feeding part appearance and hemorrhage situation respectively, the stimulation degree is also estimated in the according to the form below scoring:
Table 1 skin irritation reaction standards of grading
Table 2 skin irritation intensity standards of grading
Table 3 spray is to normal skin irritant average response value
The result: spray is to the stimulation and the blank no significant difference of normal skin as can be seen from Table 3.
The average response value that table 4 spray stimulates injured skin
The result: spray is to the stimulation and the blank no significant difference of injured skin as can be seen from Table 3.
Claims (1)
1, a kind of wound hemostasis antiinflammatory sterile dry spray is characterized in that making through the following step:
The separation of step 1, compound components of panax notoginseng:
Get Radix Notoginseng reed 1 kilogram, beat coarse powder, the ethanol with 60% soaks into, and uses supercritical SC-CO
2Extracting method extracts, and solvent is selected CO for use
2, CO
2Carry 10% methanol secretly, 45～65 ℃ of extraction temperature, extracting pressure 30～50Mpa resolves pressure 8～14Mpa, and 42～67 ℃ of resolution temperatures are at CO
2Carry methanol extraction secretly and partly obtain the about 157g of Radix Notoginseng extract;
The preparation of step 2, the aseptic micropowder of Radix Notoginseng extract:
Above-mentioned extract is dissolved in 2000ml water for injection, under 100 grades condition, with the membrane filtration below the 0.2 μ m, fine straining liquid is sent into sterile type and is sprayed dried machine and carry out the operation of aseptic spray drying, makes the about 132g of aseptic powder, takes out whole aseptic powder, under aseptic condition, add aseptic adjuvant chitin 100g, polylactic acid 45g and Radix Angelicae Sinensis oil 2ml, the porphyrize mixing carries out the aseptic ultramicronising of air-flowing type and pulverizes, and makes required uniform superfine sterile semi-finished product 262g;
The preparation of step 3, Radix Notoginseng extract sterile dry spray:
Under aseptic condition, with said extracted thing superfine sterile semi-finished product, every is encapsulated in the capsular dry powder spray medicament reservoir by 0.25g, promptly gets 1048 of Radix Notoginseng extract sterile dry sprays, and each spray contains effective extract 0.126g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101040277A CN100453070C (en) | 2003-12-13 | 2003-12-13 | Aseptic dry powder spray agent and production method in use for stopping the blood and diminishing inflammation in wound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101040277A CN100453070C (en) | 2003-12-13 | 2003-12-13 | Aseptic dry powder spray agent and production method in use for stopping the blood and diminishing inflammation in wound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1626064A CN1626064A (en) | 2005-06-15 |
| CN100453070C true CN100453070C (en) | 2009-01-21 |
Family
ID=34756904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101040277A Expired - Fee Related CN100453070C (en) | 2003-12-13 | 2003-12-13 | Aseptic dry powder spray agent and production method in use for stopping the blood and diminishing inflammation in wound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100453070C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813758A (en) * | 2012-09-07 | 2012-12-12 | 凌峰 | Anorectal administration drug |
| CN104841003A (en) * | 2014-08-19 | 2015-08-19 | 张秀华 | Compounded radix cirsii jeponici external-application sponge for arresting bleeding and preparation process thereof |
| CN106729645A (en) * | 2016-12-09 | 2017-05-31 | 苏州艾博迈尔新材料有限公司 | A kind of microtrauma hemostasis and anti-inflammation spray and preparation method thereof |
| CN106620330B (en) * | 2016-12-19 | 2018-05-22 | 河南亚都实业有限公司 | Chinese medicine hemostatic powder and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1092667A (en) * | 1993-03-19 | 1994-09-28 | 贺中胜 | Quick-acting hemostatic powder |
| CN1097622A (en) * | 1994-06-06 | 1995-01-25 | 郭文峰 | Styptic powder |
| CN1109363A (en) * | 1994-12-27 | 1995-10-04 | 苑庆祝 | Drug for traumatic injury |
| CN1137406A (en) * | 1996-04-08 | 1996-12-11 | 云南白药实业股份有限公司 | Yunan Baiyao (White Drug-Powder) tablet and preparation method thereof |
| CN1153057A (en) * | 1996-05-17 | 1997-07-02 | 云南白药实业股份有限公司 | Yunnan Baiyao aerosol and preparing method thereof |
-
2003
- 2003-12-13 CN CNB2003101040277A patent/CN100453070C/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1092667A (en) * | 1993-03-19 | 1994-09-28 | 贺中胜 | Quick-acting hemostatic powder |
| CN1097622A (en) * | 1994-06-06 | 1995-01-25 | 郭文峰 | Styptic powder |
| CN1109363A (en) * | 1994-12-27 | 1995-10-04 | 苑庆祝 | Drug for traumatic injury |
| CN1137406A (en) * | 1996-04-08 | 1996-12-11 | 云南白药实业股份有限公司 | Yunan Baiyao (White Drug-Powder) tablet and preparation method thereof |
| CN1153057A (en) * | 1996-05-17 | 1997-07-02 | 云南白药实业股份有限公司 | Yunnan Baiyao aerosol and preparing method thereof |
Non-Patent Citations (8)
| Title |
|---|
| 三七配伍应用探析. 陈文莉.江西中医药，第33卷第2期. 2002 |
| 三七配伍应用探析. 陈文莉.江西中医药，第33卷第2期. 2002 * |
| 国产血竭研究概况. 陆晖，腾建北，吴怀恩.中药材，第26卷第6期. 2003 |
| 国产血竭研究概况. 陆晖，腾建北，吴怀恩.中药材，第26卷第6期. 2003 * |
| 血竭愈烫喷雾剂的研制. 孟庆芬，张吉文，李彩凤.重庆医学，第32卷第1期. 2003 |
| 血竭愈烫喷雾剂的研制. 孟庆芬，张吉文，李彩凤.重庆医学，第32卷第1期. 2003 * |
| 重楼的研究及应用进展. 边洪荣，李小娜，王会敏.中药材，第21卷第1期. 2002 |
| 重楼的研究及应用进展. 边洪荣，李小娜，王会敏.中药材，第21卷第1期. 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1626064A (en) | 2005-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091203B (en) | External traditional Chinese medicine preparation for treating chronic wounds and preparation method thereof | |
| CN101347536B (en) | External-use preparation for treating traumatic injury | |
| CN103041173A (en) | Traditional Chinese medicine external preparation for curing dermatitis and eczema and preparing method thereof | |
| CN101518600B (en) | Chinese medicinal composition for treating bacterial or fungal dermatosis and preparation method thereof | |
| CN102228485A (en) | Composition for burn rehabilitation and preparation method thereof | |
| CN102861287B (en) | Chinese medicinal composition for treating damp-heat invasion blood stasis diabetic foot and preparation method thereof | |
| CN102772712B (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
| CN101229322A (en) | External medicine for treating surgery and dermatology department diseases and preparing method thereof | |
| CN106420564A (en) | Cornu cervi pantotrichum external restoration composition | |
| CN114010709A (en) | External traditional Chinese medicine ointment for treating myopia and preparation method thereof | |
| CN103611133A (en) | Blood circulation promotion and pain alleviation gel and preparation method thereof | |
| CN100453070C (en) | Aseptic dry powder spray agent and production method in use for stopping the blood and diminishing inflammation in wound | |
| CN102846824B (en) | Traditional Chinese medicinal composition for treating cold dampness blood stasis blocking channel type diabetic feet, and its preparation method | |
| CN108403932B (en) | Traditional Chinese medicine compound external preparation for treating hormone-dependent dermatitis and preparation method and application thereof | |
| CN102764345B (en) | Basil-bluegum ointment for curing burns and preparation method thereof | |
| CN115381912A (en) | External traditional Chinese medicine compound preparation for reducing cancer pain and preparation method thereof | |
| CN105343399B (en) | A Chinese medicinal composition and ointment for treating skin injury, and preparation method thereof | |
| CN114272182A (en) | Preparation method and application of traditional Chinese medicine composition with skin repairing effect | |
| CN103142727B (en) | Chinese herbal medicine composition for treating burning and scalding of human body | |
| CN113244356A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN105561203A (en) | Drug for treating comprehensive beriberi | |
| CN100341532C (en) | External use preparation for treating bliser tetter | |
| CN102048808A (en) | Preparation method of Lamiophlomis rotate medicinal preparation with anti-inflammatory analgesic effects | |
| CN109806321B (en) | A Chinese medicinal composition, its preparation method and application in preparing medicine for treating trauma | |
| CN111494571B (en) | Traditional Chinese medicine composition for treating damp-heat blockage type gout and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090121 Termination date: 20100113 |